Overview

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Status:
Not yet recruiting

Trial end date:
2025-01-02

Target enrollment:

Participant gender:

Summary

This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.

Phase:

Phase 2

Details

Lead Sponsor:

Drugs for Neglected Diseases

Collaborator:

Novartis Pharmaceuticals

Treatments:

Liposomal amphotericin B